U.S. markets close in 5 hours 38 minutes
  • S&P 500

    4,289.62
    -7.52 (-0.18%)
     
  • Dow 30

    33,993.30
    +80.86 (+0.24%)
     
  • Nasdaq

    13,037.64
    -90.41 (-0.69%)
     
  • Russell 2000

    2,009.31
    -12.04 (-0.60%)
     
  • Crude Oil

    89.18
    -0.23 (-0.26%)
     
  • Gold

    1,789.30
    -8.80 (-0.49%)
     
  • Silver

    20.07
    -0.20 (-1.00%)
     
  • EUR/USD

    1.0178
    +0.0013 (+0.13%)
     
  • 10-Yr Bond

    2.8530
    +0.0620 (+2.22%)
     
  • GBP/USD

    1.2095
    +0.0037 (+0.30%)
     
  • USD/JPY

    134.4240
    +1.1520 (+0.86%)
     
  • BTC-USD

    23,814.78
    -324.02 (-1.34%)
     
  • CMC Crypto 200

    566.46
    -5.45 (-0.95%)
     
  • FTSE 100

    7,542.46
    +33.31 (+0.44%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Inogen (NASDAQ:INGN) shareholders have endured a 78% loss from investing in the stock three years ago

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It's not possible to invest over long periods without making some bad investments. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of Inogen, Inc. (NASDAQ:INGN), who have seen the share price tank a massive 78% over a three year period. That'd be enough to cause even the strongest minds some disquiet. And more recent buyers are having a tough time too, with a drop of 45% in the last year. Furthermore, it's down 20% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 8.8% decline in the broader market, throughout the period.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

View our latest analysis for Inogen

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Inogen became profitable within the last five years. We would usually expect to see the share price rise as a result. So given the share price is down it's worth checking some other metrics too.

We think that the revenue decline over three years, at a rate of 3.6% per year, probably had some shareholders looking to sell. And that's not surprising, since it seems unlikely that EPS growth can continue for long in the absence of revenue growth.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

We know that Inogen has improved its bottom line lately, but what does the future have in store? So we recommend checking out this free report showing consensus forecasts

A Different Perspective

While the broader market gained around 5.9% in the last year, Inogen shareholders lost 45%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 9% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Inogen better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Inogen you should be aware of, and 1 of them is concerning.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.